Prediction of Plasma ctDNA Fraction and Prognostic Implications of Liquid Biopsy in Advanced Prostate Cancer

The authors intersected circulating tumor DNA fraction, treatment outcomes, and clinical characteristics across 738 plasma samples from 491 male mCRPC patients from two randomized multicentre Phase II trials and a prospective province-wide blood biobanking program.